Adult and Paediatric Low Grade Glioma

Subspecialty: Neuro-oncology

Type: Clinical Summary

This combined update and review summarize contemporary neuropathology-based diagnosis, important molecular subtypes, and management-relevant evidence for adult WHO grade 2 (WHO grade II / “WHO grade 2 adult-type diffuse glioma”) and pediatric low-grade gliomas (pLGG). It covers evidence-based guideline updates on neuropathology for WHO grade 2 diffuse glioma (diagnostic recommendations, molecular testing questions including ATRX and intraoperative optical methods), the phase‑3 INDIGO trial of the mutant-IDH inhibitor vorasidenib, and large pediatric series and the implications of the WHO 2021 …

Source Papers

The 2021 WHO Classification of Tumors of the Central Nervous System: An update on pediatric low-grade gliomas and glioneuronal tumors. (2022)
Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas (2020)
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (2023)
Congress of Neurological Surgeons systematic review and evidence based guideline on neuropathology for WHO grade II diffuse glioma: update. (2025)